the aid library

LIST OPTIONS

Filter

1320

Sort by:

Direction:

Download (2123)

View PDF (4594)

Best Practice Guidelines on Emergency Surgical Care in Disaster Situations

World Health Organization WHO, EHT, CPR (2005)

These guidelines have been extracted from the WHO manual Surgical Care at the District Hospital (SCDH), which is a part of the WHO Integrated Management Package on Emergency and Essential Surgical Care (IMPEESC). Refer for details on anaesthesia, head, gunshot and landmine injuries in chapters

Download (11437)

View PDF (2285)

Sterilization Manual for Health Centers

Silvia I. Acosta-Gnass and Valeska de Andrade Stempliuk PAHO; USAID (2009) C_WHO

Download (527)

View PDF (449)

Tuberculosis - A manual for medical students

N. Ait-Khaled, D. Enarson World Health Organization; International Union Against Tuberculosis and Lung Disease (1999) C_WHO

WHO/CDS/TB/99.272

Download (98)

View PDF (136)

HIV/STI prevention and care activities in a military and peacekeeping setting in Ukraine

UNAIDS (2004) C2

Country report UNAIDS Series: Engaging uniformed services in the fight against AIDS Case Study 2

Download (788)

View PDF (1118)

Zambia Demographic and Health Survey 2001-2002

Central Statistical Office Lusaka; Ministry of Health Zambia; Tropical Diseases Research Centre, Zambia, DHS; et al. (2003) C1

Download (7969)

View PDF (5647)

Practical Guidelines for Infection Control in Health Care Facilities
recommended

Manju Vatsa, Duangvadee Sungkhobol, Sudarshan Kumari, et al. WHO Western Pacific, Manila, and WHO South-East Asia, New Delhi (2004)

Download (1134)

View PDF (1649)

Management and Control of Viral Haemorrhagic Fevers and other highly contagious viral pathogens

European Network for Diagnostics of Imported Viral Diseases (2001) C1

Download (881)

View PDF (1229)

Uganda National Health Laboratory Services Policy

Federal Ministry of Health, Uganda (2009) C1

Download (495)

View PDF (1202)

Uganda: The National Policy Guidelines and Service Standards for Reproductive Health Services

Reproductive Health Division Community Health Department Ministry of Health Uganda (2002)

Download (970)

View PDF (1144)

National Antiretroviral Treatment Guidelines for Adults, Adolescents and Children

Elly T. Katabira,Moses R. Kamya, Israel Kalyesubula, Alice Namale Federal Ministry of Health, Uganda (2009) C1

Download (1498)

View PDF (980)

National Strategic Framework for Prevention and Containment of Antimicrobial Resistance

Food, Medicine and Health care Administration and Control Authority of Ethiopia (FMHACA) (2009) C1

Download (393)

View PDF (745)

Guidelines on Drug Registration Applications in Botswana

Drugs Advisory Board, Republic of Botswana (Gabarone, Botswana) (2000)

First Revised Edition March 2000

Download (275)

View PDF (391)

Indonesia: National Medicines Policy 2006

Decree of Minister of Health – Republic of Indonesia (2006) C1

Download (682)

View PDF (1483)

Plague manual: epidemiology, distribution, surveillance and control, Chapter 1-2

World Health Organization (1999) C_WHO

Download (460)

View PDF (757)

Screening donated blood for transfusion-transmissible infections: recommendations

World Health Organization (WHO) (2009) C_WHO

The provision of safe and efficacious blood and blood components for transfusion or manufacturing use involves a number of processes, from the selection of blood donors and the collection, processing and testing of blood donations to the testing of patient samples, the issue of compatible blood and ... more

Download (2375)

View PDF (1686)

Malaria Diagnosis and Treatment Guidelines for Health Workers in Ethiopia

Ministry of Health, Ethiopia (2004) C1

Download (272)

View PDF (360)

User manual for WHO cervical cancer prevention and control costing tool: HPV vaccination module (‎C4P-HPV tool)

World Health Organisation (WHO) (2023) C_WHO

Cervical cancer is the fourth most common cancer in women worldwide in 2018, with 570,000 new cases and 311,000 deaths occurring annually.T he highest incidence rates are in Southern Africa, Eastern Africa, SubSaharan Africa, Western Africa, Melanesia, and Middle Africa . It also ranks as the leadin... more

Download (154)

View PDF (140)

Risk factors of Cholera mortality

Global Task Force On Cholera Control (GTFCC) (2022) CC

To better adapt current case management practices and address excess mortality in otherwise treatable cases will require better knowledge of the demographic characteristics of the patients and comorbidities which can make severe dehydration harder to tolerate physiologically. With this in mind, a ... more

Download (98)

View PDF (97)

Tuberculosis Research Funding Trends 2005-2020

World Health Organisation (WHO) (2021) C_WHO

Previous advocacy efforts have achieved tangible goals in terms garnering political commitments to increase financing for TB—as seen at the 2018 UN High-Level Meeting on TB. The challenge now is to ensure that these commitments are actually met within a global biomedical research ecosystem that... more

Download (240)

View PDF (323)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Practical Guidelines for Infection Control in Health Care Facilities recommended

Practical Guidelines for Infection Control in Health Care Facilities
recommended